Condition

Chemotherapy-Induced Myelosuppression

ClinicalTrials.gov condition label

Clinical trials2

Recruiting0

Common interventions4

Lead sponsors shown2

Clinical trials

2 shown

Careseng 1370 for Chemotherapy-Induced MyelosuppressionNCT03692780 · 2019-03-01

WITHDRAWN

Prophylaxis of Hematologic Complications With Naderin in First-Line Breast Cancer ChemotherapyNCT07671547 · 2014-01-01

COMPLETED

Common interventions

AC ChemotherapyDRUG1Careseng 1370DRUG1NaderinDRUG1PlaceboDRUG1

Leading sponsors

Careseng Biotech Co., Ltd.1MIPO Clinic1

Trial status mix

COMPLETED1

WITHDRAWN1

Phase mix

PHASE22

PHASE11

PHASE31

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.